Navigation Links
Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
Date:3/25/2009

933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's future regulatory filings and the timing and outcome thereof. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the company's annual report on Form 10-K for the period ended Dec. 31, 2008, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

TRBN-G

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
2. Trubion Announces Presentations at Upcoming Investor Conferences
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
6. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
7. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
8. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
9. Trubion Announces Presentations at April/May Investor Conferences
10. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
11. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... Imaging Diagnostic,Systems, Inc., (OTC Bulletin Board: IMDS), a ... recent study on CTLM is one of the featured,scientific ... Dr. Jin Qi,a radiologist at the Tianjin Medical ... her paper, "CTLM as an Adjunct to Mammography,in the ...
... strong pipeline makes the,Copenhagen Region biotech cluster well prepared for ... development, Denmark,ranks third in Europe. Only United Kingdom and Germany ... Also in term of pipeline growth Denmark has a ... countries in Europe. , ...
... 1 Collexis Holdings, Inc.,(OTC Bulletin Board: ... and,knowledge discovery software, announced today a partnership ... promote BiomedExperts.com,to the association,s 200+ membership base. ... primary professional network for,BioFlorida, helping to facilitate ...
Cached Biology Technology:Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference 2Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference 3Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 3BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 4
(Date:8/27/2014)... University of Utah biologist agan Sekercioglu, who campaigns to ... nation,s highest science prize, which is similar to the ... five researchers picked for 2014 the top awards by ... Three researchers won the Science Award and two ... equivalent to the Science Award but for scientists who ...
(Date:8/27/2014)... entering what is described by the Volunteer Wildfire Services ... Eastern Cape provincial government warned residents in certain parts ... and veld fires. A high veld fire danger ... the coast in the Great Kei and Mnquma area. ... during thunderstorms. The thunderstorms bring lightning strikes and ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):University of Utah biologist wins Turkey's top science prize 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... advice twice is enough for patients to get the significant ... by doctors at St. Michael,s Hospital and the University of ... take their health into their own hands," said Dr. David ... the hospital,s Risk Factor Modification Centre. Dr. Jenkins is also ...
... same University of Washington researcher who used chemical sleuthing ... turned her attention to the scented air wafting from ... the journal Air Quality, Atmosphere and Health, ... scented liquid laundry detergent and scented dryer sheet contains ...
... M M E D I A T E ... Medicine Journal Stem cells derived from human amniotic fluid hold ... Tampa, Fla. (Aug. 24, 2011) Two papers published ... on-line at http://www.ingentaconnect.com/content/cog/ct/ , highlight the rich source of stem cells ...
Cached Biology News:No need to nag: study finds doctors' nutrition advice hits home early 2Scented laundry products emit hazardous chemicals through dryer vents 2Stem cells derived from human amniotic fluid hold promise 2Stem cells derived from human amniotic fluid hold promise 3